Xilio Therapeutics (XLO) Competitors $1.32 +0.05 (+3.94%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends XLO vs. ENTA, TSVT, NKTR, NKTX, XBIT, PYXS, MRSN, ETON, TRVI, and LFCRShould you be buying Xilio Therapeutics stock or one of its competitors? The main competitors of Xilio Therapeutics include Enanta Pharmaceuticals (ENTA), 2seventy bio (TSVT), Nektar Therapeutics (NKTR), Nkarta (NKTX), XBiotech (XBIT), Pyxis Oncology (PYXS), Mersana Therapeutics (MRSN), Eton Pharmaceuticals (ETON), Trevi Therapeutics (TRVI), and Lifecore Biomedical (LFCR). These companies are all part of the "pharmaceutical preparations" industry. Xilio Therapeutics vs. Enanta Pharmaceuticals 2seventy bio Nektar Therapeutics Nkarta XBiotech Pyxis Oncology Mersana Therapeutics Eton Pharmaceuticals Trevi Therapeutics Lifecore Biomedical Enanta Pharmaceuticals (NASDAQ:ENTA) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, community ranking, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings. Which has more volatility and risk, ENTA or XLO? Enanta Pharmaceuticals has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500. Comparatively, Xilio Therapeutics has a beta of -0.24, meaning that its share price is 124% less volatile than the S&P 500. Does the media refer more to ENTA or XLO? In the previous week, Enanta Pharmaceuticals had 1 more articles in the media than Xilio Therapeutics. MarketBeat recorded 3 mentions for Enanta Pharmaceuticals and 2 mentions for Xilio Therapeutics. Enanta Pharmaceuticals' average media sentiment score of 0.97 beat Xilio Therapeutics' score of 0.33 indicating that Enanta Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enanta Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xilio Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is ENTA or XLO more profitable? Xilio Therapeutics has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -160.27%. Enanta Pharmaceuticals' return on equity of -63.75% beat Xilio Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Enanta Pharmaceuticals-160.27% -63.75% -27.09% Xilio Therapeutics N/A -173.95%-83.00% Do analysts recommend ENTA or XLO? Enanta Pharmaceuticals presently has a consensus price target of $20.00, indicating a potential upside of 82.65%. Given Enanta Pharmaceuticals' higher probable upside, analysts plainly believe Enanta Pharmaceuticals is more favorable than Xilio Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enanta Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60Xilio Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Do insiders & institutionals believe in ENTA or XLO? 95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are owned by institutional investors. 13.6% of Enanta Pharmaceuticals shares are owned by company insiders. Comparatively, 5.2% of Xilio Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community believe in ENTA or XLO? Enanta Pharmaceuticals received 304 more outperform votes than Xilio Therapeutics when rated by MarketBeat users. However, 73.33% of users gave Xilio Therapeutics an outperform vote while only 56.76% of users gave Enanta Pharmaceuticals an outperform vote. CompanyUnderperformOutperformEnanta PharmaceuticalsOutperform Votes31556.76% Underperform Votes24043.24% Xilio TherapeuticsOutperform Votes1173.33% Underperform Votes426.67% Which has preferable earnings & valuation, ENTA or XLO? Xilio Therapeutics has lower revenue, but higher earnings than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Xilio Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnanta Pharmaceuticals$79.20M2.93-$133.82M-$5.45-2.01Xilio TherapeuticsN/AN/A-$76.40M-$2.11-0.63 SummaryEnanta Pharmaceuticals beats Xilio Therapeutics on 12 of the 17 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Xilio Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for XLO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XLO vs. The Competition Export to ExcelMetricXilio TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$58.01M$7.02B$5.33B$8.52BDividend YieldN/A7.92%5.07%4.13%P/E Ratio-0.6312.35128.4016.13Price / SalesN/A396.051,491.7792.21Price / CashN/A47.4339.5634.18Price / Book0.995.604.765.07Net Income-$76.40M$153.56M$118.92M$225.46M7 Day Performance38.95%-1.46%-0.39%0.07%1 Month Performance76.00%15.32%6.06%3.93%1 Year Performance-42.75%43.07%38.23%32.51% Xilio Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XLOXilio Therapeutics1.8149 of 5 stars$1.32+3.9%N/A-42.7%$58.01MN/A-0.6373News CoverageENTAEnanta Pharmaceuticals3.9721 of 5 stars$10.95-2.6%$20.00+82.6%+22.6%$232.03M$79.20M-2.01145Short Interest ↑TSVT2seventy bio1.7848 of 5 stars$4.40+1.4%$9.00+104.5%+88.8%$226.60M$100.39M-1.43440NKTRNektar Therapeutics4.2982 of 5 stars$1.23+3.4%$2.33+89.7%+153.6%$226.42M$90.12M-1.37220Upcoming EarningsNews CoverageNKTXNkarta2.5503 of 5 stars$3.19+3.6%$17.50+448.6%+67.0%$225.08MN/A-1.59140XBITXBiotech0.7766 of 5 stars$7.35+1.2%N/A+70.9%$223.88M$4.01M-6.34100News CoveragePYXSPyxis Oncology0.8886 of 5 stars$3.76+5.6%$9.00+139.4%+117.3%$223.42MN/A-3.0360Upcoming EarningsMRSNMersana Therapeutics3.8923 of 5 stars$1.82+0.6%$6.00+229.7%+51.0%$223.27M$29.94M-2.09150Upcoming EarningsPositive NewsETONEton Pharmaceuticals3.3912 of 5 stars$8.62+1.8%$13.00+50.8%+102.3%$222.71M$31.38M-33.1520TRVITrevi Therapeutics3.5836 of 5 stars$3.01+2.2%$7.43+146.8%+71.0%$218.50MN/A-7.7220News CoverageLFCRLifecore Biomedical3.0309 of 5 stars$5.88+3.5%$8.00+36.2%-16.4%$216.38M$128.26M73.44690Positive News Related Companies and Tools Related Companies ENTA Competitors TSVT Competitors NKTR Competitors NKTX Competitors XBIT Competitors PYXS Competitors MRSN Competitors ETON Competitors TRVI Competitors LFCR Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:XLO) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xilio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xilio Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
